- Home
- PLBY vs IXHL Comparison
PLBY vs IXHL Comparison
Compare PLBY & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLBY | IXHL |
|---|---|---|
| Founded | 1953 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 134.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PLBY | IXHL |
|---|---|---|
| Price | $1.59 | $0.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 363.5K | ★ 7.8M |
| Earning Date | 03-12-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $119,510,000.00 | $12,000.00 |
| Revenue This Year | $4.97 | N/A |
| Revenue Next Year | $8.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.90 | $0.08 |
| 52 Week High | $2.53 | $2.24 |
Technical Indicators
Market Signals| Indicator | PLBY | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 31.97 | 27.26 |
| Support Level | $1.47 | $0.25 |
| Resistance Level | $1.91 | $0.34 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 5.62 | 10.06 |
Price Performance
Historical ComparisonAbout PLBY PLBY Group Inc.
Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.